Cover Image
市場調查報告書

Evotec AG - 產品平台分析

Evotec AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 277765
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
Evotec AG - 產品平台分析 Evotec AG - Product Pipeline Review - 2016
出版日期: 2016年04月13日 內容資訊: 英文 60 Pages
簡介

Evotec AG是在合作研發藥物、共同開發企業,以及在癌症和神經及腎臟,心血管,發炎,疼痛,代謝性疾病,呼吸疾病等各種治療領域上低分子藥劑特定及開發及其他各種服務上發展事業的企業。

本報告提供Evotec AG的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Evotec AG 基本資料

Evotec AG 概要

  • 主要資訊
  • 企業資料

Evotec AG :R&D概要

  • 主要的治療範圍

Evotec AG :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Evotec AG :開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Evotec AG :藥物簡介

  • EVT-201
  • EVT-401
  • Drug To Target KDM For Oncology
  • Drugs for Endometriosis
  • EVT-501
  • Insulin Sensitizer
  • Small Molecule to Antagonize B1 for Pain
  • Small Molecule to Antagonize P2X3 and P2X2/3
  • Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis
  • Small Molecules for Inflammation
  • Small Molecules for Neurodegeneration
  • Undisclosed Molecule for Pain
  • Drug For Anemia
  • Drug for Kidney Diseases
  • Drug for Solid Tumor and Leukemia
  • Drugs for Glioblastoma Multiforme
  • Drugs for TargetEEM
  • Drugs to Inhibit FGFR3 for Cancer
  • Drugs to Inhibit Isocitrate Dehydrogenase for Cancer
  • Induced Pluripotent Stem Cells For Amyotrophic Lateral Sclerosis
  • Small Molecule For Alzheimers Disease
  • Small Molecule to Inhibit BACE-1 for Alzheimers Disease
  • Small Molecule to Inhibit PGB for Bacterial Infections
  • Small Molecule To Inhibit Serine Racemase For Neurology
  • Small Molecules for Chronic Kidney Disease
  • Small Molecules for Huntington Disease
  • Small Molecules for Multiple Sclerosis
  • Small Molecules to Inhibit Kv1.3 for Autoimmune Disorders

Evotec AG :開發平台分析

  • 各給藥途徑
  • 各分子類型

Evotec AG :最近的開發平台趨勢

Evotec AG :暫停中的計劃

Evotec AG :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • EVT-301
    • RG-1577
    • REN-1654
    • REN-213
    • REN-850

Evotec AG :企業發表

Evotec AG :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08021CDB

Summary

Global Markets Direct's, 'Evotec AG - Product Pipeline Review - 2016', provides an overview of the Evotec AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Evotec AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Evotec AG
  • The report provides overview of Evotec AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Evotec AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Evotec AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Evotec AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Evotec AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Evotec AG Snapshot
    • Evotec AG Overview
    • Key Information
    • Key Facts
  • Evotec AG - Research and Development Overview
    • Key Therapeutic Areas
  • Evotec AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Evotec AG - Pipeline Products Glance
    • Evotec AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Evotec AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Evotec AG - Drug Profiles
    • EVT-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit KDM for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Endometriosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-070
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-601
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-701
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-801
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Type 1 Diabetes and Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Kidney Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit FGFR3 for Bladder Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Chronic Kidney Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Dysferlinopathies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Huntington Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Neurodegenerative diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PGB for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Evotec AG - Pipeline Analysis
    • Evotec AG - Pipeline Products by Target
    • Evotec AG - Pipeline Products by Route of Administration
    • Evotec AG - Pipeline Products by Molecule Type
    • Evotec AG - Pipeline Products by Mechanism of Action
  • Evotec AG - Recent Pipeline Updates
  • Evotec AG - Dormant Projects
  • Evotec AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • EVT-301
      • sembragiline
      • ocaperidone
      • REN-1654
      • REN-213
      • REN-850
  • Evotec AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Evotec AG, Key Information
  • Evotec AG, Key Facts
  • Evotec AG - Pipeline by Indication, 2016
  • Evotec AG - Pipeline by Stage of Development, 2016
  • Evotec AG - Monotherapy Products in Pipeline, 2016
  • Evotec AG - Partnered Products in Pipeline, 2016
  • Evotec AG - Partnered Products/ Combination Treatment Modalities, 2016
  • Evotec AG - Out-Licensed Products in Pipeline, 2016
  • Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Evotec AG - Phase II, 2016
  • Evotec AG - Phase I, 2016
  • Evotec AG - Preclinical, 2016
  • Evotec AG - Discovery, 2016
  • Evotec AG - Pipeline by Target, 2016
  • Evotec AG - Pipeline by Route of Administration, 2016
  • Evotec AG - Pipeline by Molecule Type, 2016
  • Evotec AG - Pipeline Products by Mechanism of Action, 2016
  • Evotec AG - Recent Pipeline Updates, 2016
  • Evotec AG - Dormant Developmental Projects,2016
  • Evotec AG - Discontinued Pipeline Products, 2016
  • Evotec AG, Subsidiaries

List of Figures

  • Evotec AG - Pipeline by Top 10 Indication, 2016
  • Evotec AG - Pipeline by Stage of Development, 2016
  • Evotec AG - Monotherapy Products in Pipeline, 2016
  • Evotec AG - Partnered Products in Pipeline, 2016
  • Evotec AG - Out-Licensed Products in Pipeline, 2016
  • Evotec AG - Pipeline by Target, 2016
  • Evotec AG - Pipeline by Molecule Type, 2016
  • Evotec AG - Pipeline Products by Mechanism of Action, 2016
Back to Top